US 11,306,073 B2Granted

N-acylurea derivative and composition comprising same for prevention or treatment of cardiovascular disease

AssigneesKorea University Research and Business Foundation, Kyungpook National University Industry-Academic Coopertion Foundation

InventorsSoon Jun Hong, Chung Ho Kim, Hyung Joon Joo, Jong-Ho Kim, Ji-Young Park, Seung Cheol Choi, Chan-Sik Yang, Jong Hwa Jung, Minseon Jeong, Miseon Ryu, Sugyeong Kwon

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

The present invention relates to a novel N-acylurea derivative and the use thereof for the prevention or treatment of cardiovascular disease, and more particularly to a novel N-acylurea derivative, a pharmaceutical composition for prevention or treatment of cardiovascular disease, which contains the N-acylurea derivative as an active ingredient, and a method of preparing the N-acylurea derivative. The N-acylurea derivative according to the present invention can inhibit platelet aggregation by inhibiting the activity of talin in the intracellular matrix, and thus can be useful for the prevention or treatment of cardiovascular disease.

A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

(1) N-((4-bromo-3-methoxyphenyl) carbamoyl)-2-(5-phenyl-2H-tetrazol-2-yl)acetamide
(2) N-((4-phenoxyphenyl)carbamoyl)-2-(5-phenyl-2H-tetrazol-2-yl)acetamide
(3) N-((4-methoxybenzyl)carbamoyl)-2-(5-phenyl-2H-tetrazol-2-yl)acetamide
(4) N-((2-(3a,7a-dihydro-1H-indol-3-yl)ethyl)carbamoyl)-2-(5-phenyl-2H-tetrazol-2-yl)acetamide)
(5) N-((2,4-dimethoxyphenyl)carbamoyl)-2-(5-phenyl-2H-tetrazol-2-yl)acetamide
(6) N-((4-(benzyloxy)phenyl)carbamoyl)-2-(5-phenyl-2H-tetrazol-2-yl)acetamide
(7) N-((2-fluorophenyl)carbamoyl)-2-(5-phenyl-2H-tetrazol-2-yl)acetamide
(8) 2-(benzo[d][1,3]dioxol-5-yloxy)-N-((3-fluoropyridin-2-yl)carbamoyl)acetamide
(9) 2-(benzo[d][1,3]dioxol-5-yloxy)-N-((4-bromo-3-methoxyphenyl)carbamoyl)acetamide
(10) 2-(benzo[d][1,3]dioxol-5-yloxy)-N-((4-phenoxyphenyl)carbamoyl)acetamide
(11) 2-(benzo[d][1,3]dioxol-5-yloxy)-N-((4-methoxybenzyl)carbamoyl)acetamide
(12) N-((2-(1H-indol-3-yl)ethyl)carbamoyl)-2-(benzo[d][1,3]dioxol-5-yloxy)acetamide
(13) 2-(benzo[d][1,3]dioxol-5-yloxy)-N-((2,4-dimethoxyphenyl)carbamoyl)acetamide
(14) 2-(benzo[d][1,3]dioxol-5-yloxy)-N-((4-(benzyloxy)phenyl)carbamoyl)acetamide
(15) 2-(benzo[d][1,3]dioxol-5-yloxy)-N-((2-fluorophenyl)carbamoyl)acetamide
(16) N-((3-fluoropyridin-2-yl)carbamoyl)-2-(2-methoxyphenoxy)acetamide
(17) N-((4-bromo-3-methoxyphenyl)carbamoyl)-2-(2-methoxyphenoxy)acetamide
(18) 2-(2-methoxyphenoxy)-N-((4-phenoxyphenyl)carbamoyl)acetamide
(19) N-((4-methoxybenzyl)carbamoyl)-2-(2-methoxyphenoxy)acetamide
(20) N-((2-(1H-indol-3-yl)ethyl)carbamoyl)-2-(2-methoxyphenoxy)acetamide
(21) N-((2,4-dimethoxyphenyl)carbamoyl)-2-(2-methoxyphenoxy)acetamide
(22) N-((4-(benzyloxy)phenyl)carbamoyl)-2-(2-methoxyphenoxy)acetamide
(23) 2-(3,5-bis(trifluoromethyl)phenoxy)-N-((3-fluoropyridin-2-yl)carbamoyl)acetamide
(24) 2-(3,5-bis(trifluoromethyl)phenoxy)-N-((4-bromo-3-methoxyphenyl)carbamoyl)-acetamide
(25) 2-(3,5-bis(trifluoromethyl)phenoxy)-N-((4-methoxybenzyl)carbamoyl)acetamide
(26) N-((2-(1H-indol-3-yl)ethyl)carbamoyl)-2-(3,5-bis(trifluoromethyl)phenoxy)acetamide
(27) 2-(3,5-bis(trifluoromethyl)phenoxy)-N-((2,4-dimethoxyphenyl)carbamoyl)acetamide
(28) N-((4-(benzyloxy)phenyl)carbamoyl)-2-(3,5-bis(trifluoromethyl)phenoxy)acetamide
(29) 2-(3,5-bis(trifluoromethyl)phenoxy)-N-((2-fluorophenyl)carbamoyl)acetamide
(30) N-((4-bromo-3-methoxyphenyl)carbamoyl)-2-(3-bromophenoxy)acetamide
(31) 2-(3-bromophenoxy)-N-((2,4-dimethoxyphenyl)carbamoyl)acetamide
(32) 2-(2,3-dimethylphenoxy)-N-((2-fluorophenyl)carbamoyl)acetamide
(33) 2-(4-(benzyloxy)phenoxy)-N-((2-fluorophenyl)carbamoyl)acetamide

30 more elements

Facts

Application

16/094,826Filed 22 Dec 2016

Priority

KR 10-2016-005081726 Apr 2016

Published

US 2019/0119261 A125 Apr 2019

Granted

19 Apr 2022

Term ends

Not estimatedThe source records don’t support an estimate.

Classification27 codes

C07D 405/12
Containing two hetero rings: linked by a chain containing hetero atoms as chain links
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 9/145
Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried,…: with…
A61K 9/2018
Organic compounds, e.g. phospholipids, fats: sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Abstract

Claims8